Published in Blood on June 13, 2006
GEM05 for Patients With Multiple Myeloma More Than 65 Years Old | NCT00443235
Multiple myeloma. Blood (2008) 5.88
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia (2009) 4.91
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
Proteasome inhibitors in multiple myeloma: 10 years later. Blood (2012) 2.77
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol (2008) 2.64
Treatment of multiple myeloma. Nat Rev Clin Oncol (2011) 2.46
Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech (2008) 2.37
Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol (2007) 2.14
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol (2009) 1.92
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood (2009) 1.86
Proteasome inhibitors in the treatment of multiple myeloma. Leukemia (2009) 1.68
Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica (2010) 1.32
Treatment of newly diagnosed myeloma. Leukemia (2008) 1.27
Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res (2009) 1.25
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia (2008) 1.25
Restoration of chemosensitivity by bortezomib: implications for refractory myeloma. Nat Rev Clin Oncol (2009) 1.22
Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst (2008) 1.11
Proteasome-dependent processing of topoisomerase I-DNA adducts into DNA double strand breaks at arrested replication forks. J Biol Chem (2009) 1.11
Natural compounds with proteasome inhibitory activity for cancer prevention and treatment. Curr Protein Pept Sci (2008) 1.07
Multiple myeloma. Curr Probl Cancer (2009) 1.04
Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. Br J Haematol (2008) 0.96
Efficacy of bortezomib as first-line treatment for patients with multiple myeloma. Clin Med Insights Oncol (2013) 0.95
High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients. Cancer (2008) 0.90
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol (2012) 0.90
The risk factors for herpes zoster in bortezomib treatment in patients with multiple myeloma. Korean J Hematol (2010) 0.89
New therapies in multiple myeloma. Clin Exp Med (2007) 0.86
BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein. Blood (2014) 0.84
Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. J Cancer Res Clin Oncol (2012) 0.83
Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy. Cancer Chemother Pharmacol (2013) 0.83
Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis. PLoS One (2014) 0.83
Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity. Asian J Androl (2012) 0.81
Front-line treatment in younger patients with multiple myeloma. Semin Hematol (2009) 0.81
Multiple Myeloma, Version 2.2016. J Natl Compr Canc Netw (2015) 0.81
Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells. Pharmacol Res (2013) 0.80
Novel agents for the treatment of multiple myeloma: proteasome inhibitors and immunomodulatory agents. J Adv Pract Oncol (2013) 0.80
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood (2015) 0.80
Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment. Chin J Cancer Res (2013) 0.79
Advances in multiple myeloma therapy during two past decades. Comput Struct Biotechnol J (2014) 0.79
New Treatment Approaches for Older Adults with Multiple Myeloma. J Geriatr Oncol (2012) 0.79
Are ongoing trials on hematologic malignancies still excluding older subjects? Haematologica (2013) 0.78
Review of thalidomide in the treatment of newly diagnosed multiple myeloma. Ther Clin Risk Manag (2007) 0.78
Front line treatment of elderly multiple myeloma in the era of novel agents. Biologics (2009) 0.78
Infections in Hospitalised Patients with Multiple Myeloma: Main Characteristics and Risk Factors. Turk J Haematol (2015) 0.77
Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates. Cancer J (2009) 0.77
Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study. World J Surg Oncol (2014) 0.77
Multi-Scale Agent-Based Multiple Myeloma Cancer Modeling and the Related Study of the Balance between Osteoclasts and Osteoblasts. PLoS One (2015) 0.75
Novel therapies delay the progression of smoldering multiple myeloma: Case report and discussion. Ecancermedicalscience (2010) 0.75
Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias. Biologics (2008) 0.75
Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma. J Res Med Sci (2012) 0.75
Is there a role for 'modified VAD' in the treatment of multiple myeloma? Ecancermedicalscience (2009) 0.75
Bortezomib inhibits cell proliferation in prostate cancer. Exp Ther Med (2015) 0.75
Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma. Hosp Pharm (2015) 0.75
Induction chemotherapy before autologous stem cell transplantation for symptomatic plasma cell myeloma - does it matter? Clin Pharmacol (2010) 0.75
Recurrent Body Rash Warranted Second Desensitization With Acyclovir in a Myeloma Patient: A Case Report. J Clin Med Res (2017) 0.75
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med (2013) 6.21
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol (2011) 5.67
Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med (2012) 5.16
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood (2010) 4.52
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.30
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol (2007) 3.54
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2006) 3.39
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med (2015) 3.18
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol (2002) 2.88
Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica (2005) 2.87
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood (2011) 2.82
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood (2008) 2.74
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol (2009) 2.59
Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood (2011) 2.58
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood (2011) 2.37
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol (2009) 2.32
Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica (2008) 2.32
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol (2008) 2.30
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol (2010) 2.24
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13
Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol (2008) 2.09
Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. Haematologica (2002) 2.08
Incidence of Wra antigen and anti-Wra in a Spanish population. Transfusion (2005) 2.05
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood (2008) 2.04
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. Am J Hematol (2015) 2.03
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res (2013) 2.02
Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res (2009) 1.95
Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res (2008) 1.94
Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica (2005) 1.93
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol (2009) 1.92